The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.27 and a beta of 1.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.55 and a quick ratio of 2.54. 83.48% of the stock is owned by institutional investors and hedge funds. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider’s stock worth $71,000 after buying an additional 808 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its stake in BioLife Solutions by 18.7% during the 2nd quarter. now owns 73,437 shares of the medical equipment provider’s stock valued at $1,014,000 after purchasing an additional 766 shares during the period. boosted its position in BioLife Solutions by 1.1% during the 2nd quarter. Texas Permanent School Fund now owns 21,901 shares of the medical equipment provider’s stock worth $302,000 after purchasing an additional 642 shares during the last quarter. Texas Permanent School Fund lifted its holdings in shares of BioLife Solutions by 3.0% in the 2nd quarter. Spears Abacus Advisors LLC now owns 23,143 shares of the medical equipment provider’s stock worth $863,000 after purchasing an additional 614 shares during the period. Spears Abacus Advisors LLC raised its position in shares of BioLife Solutions by 2.7% during the 4th quarter. Public Sector Pension Investment Board now owns 56,525 shares of the medical equipment provider’s stock worth $781,000 after acquiring an additional 565 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in BioLife Solutions by 1.0% in the second quarter. Several hedge funds and other institutional investors have recently modified their holdings of the business. Insiders have sold 19,602 shares of company stock worth $330,022 in the last ninety days. The disclosure for this sale can be found here. Following the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The shares were sold at an average price of $15.79, for a total value of $144,604.82. Also, COO Greef Roderick De sold 9,158 shares of the company’s stock in a transaction that occurred on Tuesday, July 12th. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Following the completion of the transaction, the executive now owns 36,218 shares in the company, valued at approximately $725,446.54. The stock was sold at an average price of $20.03, for a total value of $92,138.00.
In other news, CRO Marcus Schulz sold 4,600 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, August 3rd. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Following the completion of the sale, the executive now owns 36,218 shares of the company’s stock, valued at approximately $725,446.54. The shares were sold at an average price of $20.03, for a total value of $92,138.00. In other news, CRO Marcus Schulz sold 4,600 shares of the business’s stock in a transaction dated Wednesday, August 3rd. Insider Buying and Selling at BioLife Solutions According to, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $38.00. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock.
Finally, Oppenheimer upgraded BioLife Solutions from a “market perform” rating to an “outperform” rating in a research note on Monday, April 25th. Riley cut their price objective on shares of BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. Cowen lowered their price target on shares of BioLife Solutions from $50.00 to $32.00 in a report on Tuesday, May 10th. Maxim Group lowered their price objective on shares of BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Other analysts also recently issued research reports about the stock. The stock had previously closed at $26.01. Approximately 3,740 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 353,696 shares. The stock traded as low as $23.69 and last traded at $23.71.
( NASDAQ:BLFS – Get Rating) was down 8.8% on Tuesday after Cowen lowered their price target on the stock to $29.00.